Gamma Vaccines Pty Ltd is an Australian company targeting primarily the human and avian influenza market.
Formed in July 2009, the company is developing a cross-protective influenza virus vaccine, GammaFlu®, designed to replace current seasonal injectable flu vaccines with an easy-to-administer, broader-spectrum intranasal vaccine. The Company’s products also hold the prospect of being able to be stockpiled for use as an immediate first response to any new influenza pandemic. In addition, Gamma Vaccines is developing a vaccine that can provide better protection against highly pathogenic avian influenza in poultry. The Company is also conducting research on vaccines for preventing bacterial pneumonia.
Gamma Vaccines’ proprietary technology was invented by leading researchers from The Australian National University’s John Curtin School of Medical Research and The University of Adelaide’s School of Molecular Life Sciences. The company has attracted significant equity investments from Australian, Indonesian & US investors and been awarded numerous grants from the Australian Capital Territory and the Commonwealth Government of Australia.
For further information about Gamma Vaccines please contact Professor Tim Hirst
- Website: https://www.gammavaccines.com/index.html
- E-mail: [email protected]
- Telephone: +61 420 942 824
- Write to: Gamma Vaccines Pty Limited PO Box 4435 Manuka ACT 2603 Australia